Alkermes Acquires Rodin Therapeutics for up to $850 million
Alkermes and Rodin Therapeutics announced that they have entered into a definitive agreement under which Alkermes will acquire Rodin, a privately held biopharmaceutical company focused on developing novel, small molecule therapeutics for synaptopathies. This transaction builds on Alkermes' experience